Eli Lily and Boehringer Ingelheim's (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults withT2D and Cardiovascular Disorders
Shots:
- Lily and BI reports results of EMPA-REG OUTCOME trial assessing Jardiance (10/25 mg qd) vs PBO- from 42 countries in 7-020 patients with T2D at high risk for cardiovascular events
- EMPA-REG OUTCOME results: mean survival @age 45 yrs. (32.1 yrs vs 27.6yrs); @age 50-60-70 & 80yrs. (3.1-2.5- 2-1 yrs.)
- Jardiance is a prescription drug indicated to lower blood sugar & reduce the risk of cardiovascular death in adults with T2D. In 2011- Eli Lily & BI entered into a collaboration agreement to jointly develop Jardiance for T2D
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
